Circulating immunocompetent cell profiles during oral cyclosporin therapy for immunoglobulin-resistant Kawasaki disease  

作　　者：Seigo Okada Yuji OhnishiTakashi Furuta Yasuo Suzuki Akiko Kawakami-Miyake Chie Matsuguma Takako Waniishi Hiroki Yasudo Shunji Hasegawa 

机构地区：[1]Department of Pediatrics,Yamaguchi University Graduate School of Medicine,1-1-1 Minamikogushi,Ube,Yamaguchi 755-8505,Japan

出　　处：《World Journal of Pediatrics》2021年第6期671-673,共3页世界儿科杂志（英文版）

基　　金：supported in part by JSPS KAKENHI Grant Number JP19K08323(H.S.)from the Ministry of Education,Culture,Sports.

摘　　要：Although the standard treatment for Kawasaki disease(KD)is intravenous immunoglobulin(IVIG)combined with oral aspirin,18%of 1st IVIG is refractory[1].Recently,the efficacy of immunomodulatory drugs for IVIG-resistant KD,such as prednisolone,infliximab(IFX),and cyclosporine(CsA),has been reported[2-5].However,optimal immunomodulatory therapy for IVIG-resistant KD has not yet been established.

关 键 词：IMMUNO drugs IMMUNOGLOBULIN 

分 类 号：R725.4[医药卫生—儿科]